A61K 2039/522
Avirulent or attenuated
Official title: {avirulent or attenuated}
A61K2039/522 (Avirulent or attenuated) appears on 877 US grants and 1,181 published applications in this corpus.
Search patents in A61K- Granted patents
- 877
- Published applications
- 1,181
- Assignees
- 596
- Inventors
- 1,921
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 3 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 6 | 0 |
| 1996 | 5 | 0 |
| 1997 | 9 | 0 |
| 1998 | 11 | 0 |
| 1999 | 11 | 0 |
| 2000 | 15 | 0 |
| 2001 | 13 | 5 |
| 2002 | 12 | 21 |
| 2003 | 10 | 29 |
| 2004 | 13 | 42 |
| 2005 | 24 | 39 |
| 2006 | 21 | 38 |
| 2007 | 16 | 42 |
| 2008 | 15 | 44 |
| 2009 | 16 | 41 |
| 2010 | 40 | 59 |
| 2011 | 36 | 57 |
| 2012 | 34 | 60 |
| 2013 | 37 | 49 |
| 2014 | 48 | 53 |
| 2015 | 50 | 53 |
| 2016 | 57 | 73 |
| 2017 | 46 | 62 |
| 2018 | 50 | 55 |
| 2019 | 48 | 49 |
| 2020 | 43 | 55 |
| 2021 | 40 | 50 |
| 2022 | 35 | 50 |
| 2023 | 30 | 55 |
| 2024 | 25 | 45 |
| 2025 | 15 | 40 |
| 2026 | 19 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Use of E. coli strains expressing high level of α-Gal to modulate immunity and provide protection against infectious diseases in animals29 Sep 2026US 12,745,790 B2Biologicke Centrum AV CR v. v. i.
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- Live attenuated strain of Streptococcus pneumoniae and pharmaceutical compositions comprising a live attenuated strain of S. pneumoniae4 Aug 2026US 12,698,471 B2UCL Business PLC
- Coronavirus vaccine based on controllable secretory expression of attenuated salmonella, preparation method therefor, and application thereof7 Jul 2026US 12,673,099 B2Jiangsu Target Biomedical Research Institute Co., Ltd.
- Live attenuated non-transmissible vaccines7 Jul 2026US 12,674,131 B2University of Maryland, Baltimore
- Live attenuated leishmania parasite vaccines with enhanced safety characteristics17 Sep 2026US 2026/0273036 A1Ohio State Innovation Foundation
- Materials and Methods For Cell-Free Expression of Vaccine Epitope Concatemers27 Aug 2026US 2026/0250332 A1Leidos, Inc.
- Tumor-targeting pharmaceutical combinations30 Jul 2026US 2026/0216257 A1Baccine Ltd.
- Acinetobacter vaccine and method of use thereof9 Jul 2026US 2026/0191944 A1Washington University
- Liver disease treatments using attenuated strains of salmonella typhimurium2 Jul 2026US 2026/0183346 A1Salspera, LLC
Most cited
By later US patents
- Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response111US 5,830,702 AThe Trustees of the University of Pennsylvania · 1998
- Avirulent microbes and uses therefor: Salmonella typhi109US 5,387,744 AWashington University · 1995
- Avirulent microbes and uses therefor: salmonella typhi103US 5,294,441 AWashington University · 1994
- Vaccines containing avirulent phop-type microorganisms101US 5,424,065 AWashington University · 1995
- Shigella vector for delivering DNA to a mammalian cell99US 5,824,538 AThe United States of America as represented by the Secretary of the Army · 1998